Medicus Pharma pivots to precision oncology, prioritizing CD228V melanoma proof-of-concept study
MDCX•SkinJect to focus on Gorlin syndrome
SkinJect development will concentrate on Gorlin syndrome, targeting an NDA-enabling Phase 2b registrational study authorized by the FDA.
Teverelix programs remain in development
Teverelix will focus on a roughly 126-patient Phase 2 acute urinary retention program, alongside the PRECISION-E2 Phase 2a endometriosis study.
Medicus shifts strategy toward precision oncology
Medicus shifted strategy to become a precision oncology-led biotech, prioritizing CD228V as its main development and capital focus.
The initial goal is clinical proof-of-concept for CD228V in relapsed or refractory melanoma, supported by a biomarker-led translational plan.
Other programs to be advanced through partnerships
Other programs will be advanced through capital-efficient partnerships to preserve cash while pursuing additional clinical opportunities.
